Texas coup for SolasCure as it takes wound care tech Stateside
The programme, which is focused on commercialising innovative solutions for unmet healthcare needs, is delivered in partnership with the Texas Medical Centre (TMC), the largest medical complex globally.
The programme will support the future entry of Aurase Wound Gel, SolasCure’s first investigational product for the treatment of millions of patients with chronic wounds worldwide, into the US market.
SolasCure is one of 16 healthcare companies chosen for the Global Incubator Programme. Its participation builds on the recent European Innovation Council’s Accelerator Grant and Innovate UK Biomedical Catalyst Grant wins to further advance the development of Aurase Wound Gel.
The six-month Global Incubator Programme is fully funded by Innovate UK and includes two intensive market visits to Houston, a dynamic health research hub with over 1,760 life science companies, healthcare facilities and research institutions.
These visits will focus on customer discovery, mentorship, and investor networking, including engagement with hospital administrators, procurement, and reimbursement professionals, to support the future entry of Aurase Wound Gel for the US market.
SolasCure CEO, Lee Harle, said: “It is a real boost to our journey at SolasCure to be selected for this Global Incubator Programme, continuing the momentum from our recent EIC Accelerator and the BMC grant wins. This represents another key piece of industry validation and recognition by TMC/TMC-Innovation, global leaders in medical innovation, that SolasCure has the potential to address a huge unmet need.
“TMC is the largest medical complex in the world and gaining access to this expertise and network will be invaluable in strengthening our plans for SolasCure and Aurase Wound Gel in the US.”
• Cambridge life science company, PhoreMost, has triggered a second milestone payment in a multi-project target discovery collaboration with Boehringer Ingelheim. The amount is being kept under wraps. It was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies to transform patients’ lives.